Get the Stockscreener App
47.91
0.08%
0.04
After Hours:
47.01
-0.90
-1.88%
Tourmaline Bio Inc stock is traded at $47.91, with a volume of 249.61K.
It is up +0.08% in the last 24 hours and up +0.63% over the past month.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$47.87
Open:
$47.87
24h Volume:
249.61K
Relative Volume:
0.32
Market Cap:
$1.23B
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
82.82
EPS:
0.5785
Net Cash Flow:
$-19.23M
1W Performance:
+0.08%
1M Performance:
+0.63%
6M Performance:
+265.73%
1Y Performance:
+90.50%
1-Day Range:
$47.86
$47.91
1-Week Range:
$47.83
$47.92
52-Week Range:
$11.56
$48.27
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Compare TRML with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
47.91 | 1.23B | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Nov-11-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
Why Tourmaline Bio Inc. is moving todayMarket Growth Summary & Short-Term Trading Opportunity Alerts - newser.com
Developing predictive dashboards with Tourmaline Bio Inc. dataTrade Analysis Summary & Short-Term Trading Alerts - newser.com
What analysts say about Tourmaline Bio Inc stockInsider Trading Compliance & Learn What Analysts Rate “Strong Buy” - earlytimes.in
Is Tourmaline Bio Inc. stock a top pick in earnings season2025 Major Catalysts & Smart Allocation Stock Tips - newser.com
How to forecast Tourmaline Bio Inc. trends using time series2025 Investor Takeaways & Safe Capital Growth Stock Tips - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Tourmaline Bio (NASDAQ:TRML) - MarketBeat
How to read the order book for Tourmaline Bio Inc.Recession Risk & AI Optimized Trade Strategies - newser.com
Can a trend reversal in Tourmaline Bio Inc. lead to recoveryTrade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com
$HAREHOLDER ALERT: The M&A Class Action Continues to Investigate Merger – TRML, PNFP, MRCC, and UNP - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
MarketsMedicine Hat News - FinancialContent
Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc.TRML - FinancialContent
Custom strategy builders for tracking Tourmaline Bio Inc.Fed Meeting & Daily Growth Stock Tips - newser.com
Will Tourmaline Bio Inc. stock outperform growth indexesJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
Using flow based indicators on Tourmaline Bio Inc.2025 Year in Review & Reliable Volume Spike Trade Alerts - newser.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Sees Large Decline in Short Interest - MarketBeat
Is Tourmaline Bio Inc. forming a bottoming baseWatch List & Fast Entry Momentum Alerts - newser.com
What MACD signals say about Tourmaline Bio Inc.Portfolio Performance Report & Accurate Technical Buy Alerts - newser.com
Can Tourmaline Bio Inc. recover in the next quarter2025 Big Picture & Technical Entry and Exit Alerts - newser.com
Technical analysis overview for Tourmaline Bio Inc. stockJuly 2025 Price Swings & Community Trade Idea Sharing Platform - newser.com
Is Tourmaline Bio Inc. stock a buy in volatile marketsJuly 2025 Earnings & Fast Entry and Exit Trade Plans - newser.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Rating of "Hold" by Analysts - MarketBeat
Identifying reversal signals in Tourmaline Bio Inc.Earnings Risk Summary & Safe Entry Zone Tips - newser.com
Tourmaline Bio (TRML) Price Target Decreased by 14.70% to 48.90 - MSN
Novartis commences tender offer to buy Tourmaline Bio - Medical Dialogues
Tourmaline Bio stock hits 52-week high at 47.8 USD By Investing.com - Investing.com Nigeria
Tourmaline Bio stock hits 52-week high at 47.8 USD - Investing.com
Tourmaline Bio (NASDAQ:TRML) Sets New 52-Week HighHere's Why - MarketBeat
Tourmaline Bio Inc Stock Analysis and ForecastDebt-to-Equity Ratio Analysis & Unlock Long-Term Capital Growth Ideas - earlytimes.in
Novartis announces commencement of tender offer to acquire Tourmaline Bio29.09.25News - Ariva
Novartis launches tender offer for Tourmaline Bio - MarketScreener
Is Tourmaline Bio Inc a good long term investmentBull Market Opportunities & Outstanding Investment Returns - earlytimes.in
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):